Zynex targets $27M Q2 revenue amid restructuring and FDA submission for NiCO

Earnings Call Insights: Zynex, Inc. (ZYXI) Q1 2025 Management View CEO Thomas Sandgaard addressed the company's challenges, including the temporary payment suspension from TriCare, which impacted revenue calculations. The company is restructuring its operations to adapt to a worst-case scenario without TriCare payments, with.